CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an update.
CSPC Pharmaceutical Group has announced that its product, Oseltamivir Phosphate for Suspension, has received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in the anti-infective therapeutic area, potentially strengthening its market position and offering new treatment options for influenza A and B.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing and producing a wide range of pharmaceutical products, with a particular emphasis on anti-infectives.
YTD Price Performance: 8.47%
Average Trading Volume: 29,601
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.83B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.